Dizal Pharmaceutical
↗Shanghai, China
Dizal Pharmaceutical is a global, innovation-driven biopharmaceutical company focused on the discovery, development, and commercialization of differentiated therapeutics for oncology and immunological diseases. Established in 2017 as a joint venture between AstraZeneca and the Chinese Future Industry Investment Fund (FIIF), the company leverages advanced translational science and molecular design to build a competitive, global pipeline.
Dizal has successfully transitioned from a clinical-stage entity to a commercial-stage company with assets approved in both China and the U.S. The company is committed to addressing high unmet medical needs through first-in-class and groundbreaking medicines, with a strategy that emphasizes global synchronous development for its pipeline candidates.
CLASSIFICATION
SIZE & FINANCIALS
Employees:1001-5000
Revenue:$100M-$150M
Founded:2017
Ownership:public
Status:operating
FUNDING
Stage:Post-IPO
Total Raised:$100M (Series A)
Investors:Lilly Asia Ventures, Sequoia Capital, Trinity, Wuxi NewForce Fund
STOCK
Exchange:SSE
Ticker:688192
Market Cap:$3.88B
PIPELINE
Stage:Commercial
Lead Drug Stage:Commercial
Modalities:Small molecule
Trial Phases:-
FDA Approvals:1
EMA Approvals:0
CORPORATE STRUCTURE
Key Partnerships:AstraZeneca (Joint venture partner)
COMPETITION
Position:Emerging
Competitors:Takeda Pharmaceutical, Johnson & Johnson
LEADERSHIP
Key Executives:
Xiaolin Zhang - CEO
LINKS
Website:dizalpharma.com
⚠
Is this information incorrect? This profile was AI-generated from publicly available sources and may contain errors. If you are a representative of Dizal Pharmaceutical and believe any information on this page is inaccurate, we will promptly correct or remove it.REPORT AN ERROR
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Dizal Pharmaceutical. The information on this page was compiled using AI from publicly available sources and may be incomplete, outdated, or contain errors. We are committed to correcting inaccuracies promptly upon notice. For official information, please visit the company's website directly.